Literature DB >> 19665480

A promising new approach of VEGFR2-based DNA vaccine for tumor immunotherapy.

Jinqi Yan1, Rui Jia, Hongbin Song, Ying Liu, Liang Zhang, Wei Zhang, Yu Wang, Yunfeng Zhu, Jiyun Yu.   

Abstract

AIM: To develop new approach for tumor immunotherapy with VEGFR2-based DNA vaccine.
METHODS: VEGFR2 derived from different species were prepared by RT-PCR and subjected to recombinant constructs. The chimeric gene of VEGFR2 was prepared by integrating different epitopes in different species. By transfecting into cells, the immunological effect was evaluated with the approaches of ELISA, ELISPOT, and animal experiments.
RESULTS: (1) All these constructs, in particular chimeric construct, can result in both humoral- and cellular-immune response in BALB/c mice after immunization evaluated by the ratio of CD4+/CD8+ and release of IFN-gamma and IL-4 respectively. (2) Mice were vaccinated with these constructs and challenged with renal carcinoma cells subsequently. It manifested that tumor growth was suppressed significantly in the mice vaccinated by chimeric VEGFR2 construct.
CONCLUSION: Our results manifested that VEGFR2-based DNA chimeric vaccine could be developed as a promising approach for tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19665480     DOI: 10.1016/j.imlet.2009.07.013

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  7 in total

1.  A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature.

Authors:  Jason M Warram; Anna G Sorace; Reshu Saini; Heidi R Umphrey; Kurt R Zinn; Kenneth Hoyt
Journal:  J Ultrasound Med       Date:  2011-07       Impact factor: 2.153

Review 2.  Vascular endothelial growth factor receptor-2 in breast cancer.

Authors:  Shanchun Guo; Laronna S Colbert; Miles Fuller; Yuanyuan Zhang; Ruben R Gonzalez-Perez
Journal:  Biochim Biophys Acta       Date:  2010-05-11

3.  A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?

Authors:  Domenico Ciliberto; Nicoletta Staropoli; Francesca Caglioti; Simona Gualtieri; Lucia Fiorillo; Silvia Chiellino; Antonina Maria De Angelis; Francesco Mendicino; Cirino Botta; Michele Caraglia; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Cancer Biol Ther       Date:  2015-06-10       Impact factor: 4.742

4.  Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity.

Authors:  Jie Zhang; Ying Wang; Yang Wu; Zhen-Yu Ding; Xin-Mei Luo; Wu-Ning Zhong; Jie Liu; Xiang-Yu Xia; Guo-Hua Deng; Yao-Tiao Deng; Yu-Quan Wei; Yu Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-14       Impact factor: 4.553

5.  Immunosurveillance by antiangiogenesis: tumor growth arrest by T cell-derived thrombospondin-1.

Authors:  Keri L Schadler; Erika J Crosby; Alice Yao Zhou; Dong Ha Bhang; Lior Braunstein; Kwan Hyuck Baek; Danielle Crawford; Alison Crawford; Jill Angelosanto; E John Wherry; Sandra Ryeom
Journal:  Cancer Res       Date:  2014-03-03       Impact factor: 12.701

6.  Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax™.

Authors:  Thomas E Ichim; Shuang Li; Hong Ma; Yuliya V Yurova; Julia S Szymanski; Amit N Patel; Santosh Kesari; Wei-Ping Min; Samuel C Wagner
Journal:  J Transl Med       Date:  2015-03-14       Impact factor: 5.531

7.  Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs.

Authors:  Sofie Denies; Laetitia Cicchelero; Ingeborgh Polis; Niek N Sanders
Journal:  Oncotarget       Date:  2016-03-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.